Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 14, 2026, 10:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Drug-Interactions Clear all
Completed No phase listed Observational

Gene-Environment Interactions in Rheumatoid Arthritis Autoimmunity Disease Severity

NCT00594451
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Not listed
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 31, 2023 · Synced Sep 14, 2026, 10:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparison of KADIAN 100 mg When Dosed With Alcohol Under Fasting and Fed Conditions Compared to Water

NCT00768183
View directory record Official record
Conditions
Healthy
Interventions
KADIAN Capsule + alcohol (under fasting conditions), KADIAN Capsule + water (under fasting conditions), morphine sulfate IR oral solution + water, KADIAN Capsule + alcohol (under fed conditions)
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
21 Years to 40 Years · Male only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 15, 2020 · Synced Sep 14, 2026, 10:45 AM EDT
Completed Not applicable Interventional

Drug & Gene Interaction Risk Analysis With & Without Genetic Testing Among Patients Undergoing MTM

NCT02428660
View directory record Official record
Conditions
Cytochrome P450 CYP2D6 Enzyme Deficiency, Poor Metabolizer Due to Cytochrome P450 CYP2D6 Variant, Ultrarapid Metabolizer Due to Cytochrome P450 CYP2D6 Variant, Extensive Metabolizer Due to Cytochrome P450 CYP2D6 Variant, Cytochrome P450 CYP2C9 Enzyme Deficiency, Cytochrome P450 CYP2C19 Enzyme Deficiency, Drug Metabolism, Poor, CYP2D6-RELATED, Drug Metabolism, Poor, CYP2C19-RELATED, CYP2D6 Polymorphism
Interventions
Pharmacogenetic testing, Software-based drug & gene interaction risk analysis, MTM
Genetic · Other
Lead sponsor
Genelex Corporation
Industry
Eligibility
65 Years and older
Enrollment
341 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 22, 2017 · Synced Sep 14, 2026, 10:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-drug Interaction Study of S-892216 Coadministered With Carbamazepime to Healthy Adult Participants

NCT06751017
View directory record Official record
Conditions
COVID-19
Interventions
S-892216, Carbamazepine
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Sep 14, 2026, 10:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Effects of Fluvoxamine on Savolitinib Exposure in Healthy Male Subjects

NCT05888207
View directory record Official record
Conditions
Healthy Male Subjects
Interventions
Savolitinib, Fluvoxamine
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 28, 2023 · Synced Sep 14, 2026, 10:45 AM EDT
Recruiting No phase listed Observational

Modeling Host-Pathogen Interaction Using Lymphoid Organoids

NCT06479837
View directory record Official record
Conditions
Staphylococcal Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 120 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2044
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 13, 2026 · Synced Sep 14, 2026, 10:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Pharmacokinetic Drug-drug Interactions Between VX-993 and Metformin in Healthy Adults

NCT06523595
View directory record Official record
Conditions
Pain
Interventions
VX-993, Metformin
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 30, 2025 · Synced Sep 14, 2026, 10:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Antacid Interaction Study

NCT01982201
View directory record Official record
Conditions
Healthy
Interventions
Lesinurad 400 mg, Tums 500 mg and 750 mg, MINTOX 10 mL
Drug
Lead sponsor
Ardea Biosciences, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Sep 14, 2026, 10:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating Effects of Multiple-Dose Administration of Itraconazole on the Single Dose Pharmacokinetics of Conjugated Estrogens/Bazedoxifene in Non-Obese and Obese Postmenopausal Women

NCT02100553
View directory record Official record
Conditions
Healthy
Interventions
CE/BZA, Itraconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
40 Years to 64 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
2
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 24, 2015 · Synced Sep 14, 2026, 10:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Effect of GSK3640254 on the Pharmacokinetics of Tenofovir Alafenamide/Emtricitabine

NCT03836729
View directory record Official record
Conditions
HIV Infections
Interventions
Tenofovir alafenamide/emtricitabine, GSK3640254
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 20, 2020 · Synced Sep 14, 2026, 10:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Measure if There is Any Difference in How the Body Breaks Down or Inactivates Either Fluoxetine or LY2216684 When Both of These Medicines Are Given Together.

NCT01243957
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
LY2216684, Fluoxetine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 28, 2019 · Synced Sep 14, 2026, 10:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-drug Interaction Study Between EDP-305, Intraconazole and Rifampin in Healthy Volunteers

NCT03213145
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
intraconazole, Rifampin, EDP 305
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced Sep 14, 2026, 10:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Drug Interaction Potential Between Dolutegravir and Simeprevir in HIV/HCV Seronegative Volunteers

NCT02404805
View directory record Official record
Conditions
HIV, Hepatitis C
Interventions
dolutegravir, simeprevir
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 16, 2021 · Synced Sep 14, 2026, 10:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn if the Study Medicine Called Carbamazepine Changes How the Body Processes PF-07220060

NCT06897683
View directory record Official record
Conditions
Healthy Adults
Interventions
PF-07220060, Carbamazepine ER Tablet
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Sep 14, 2026, 10:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Drug Interaction Between Povorcitinib and the Oral Contraceptive Levonorgestrel/Ethinyl Estradiol in Healthy Adult Females

NCT06380205
View directory record Official record
Conditions
Healthy Participants
Interventions
Povorcitinib, Levonorgestrel/Ethinyl estradiol
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 60 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 2, 2024 · Synced Sep 14, 2026, 10:45 AM EDT
Completed Phase 2 Interventional

PK Effects of Bifeprunox & Valproate in Bipolar I

NCT00141505
View directory record Official record
Conditions
Bipolar I Disorder
Interventions
Bifeprunox
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 15, 2015 · Synced Sep 14, 2026, 10:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Interaction of Two HIV Medications With Blood Clot Medications in Healthy Volunteers

NCT01896622
View directory record Official record
Conditions
HIV
Interventions
Ritonavir, Cobicistat
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 14, 2026, 10:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Evaluate Safety, Tolerability, PK, and PK Interactions of TBA-7371

NCT03199339
View directory record Official record
Conditions
Tuberculosis, Tuberculosis, Pulmonary
Interventions
TBA-7371, Placebo
Drug
Lead sponsor
Global Alliance for TB Drug Development
Other
Eligibility
19 Years to 50 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Sep 14, 2026, 10:45 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

VH3739937 Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers Including Relative Bioavailability (RBA), Optional Food Effect (FE), and Drug-drug Interaction (DDI)

NCT06533280
View directory record Official record
Conditions
HIV Infections
Interventions
Part A, C and D: VH3739937 500 mg, Part A: VH3739937 100 mg, Part A and C: Placebo, Part B: Treatment A, Part B: Treatment B, Part B: Treatment C, Part B: Treatment D, Part B: Treatment E, Part D: Probe cocktail
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 21, 2025 · Synced Sep 14, 2026, 10:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Estimate The Effect Of Ketoconazole On The Pharmacokinetics Of Pf-04937319 In Healthy Subjects

NCT01468714
View directory record Official record
Conditions
Human Volunteers
Interventions
PF-04937319 / ketoconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 15, 2011 · Synced Sep 14, 2026, 10:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effects of Rifampin on the Pharmacokinetics of Rosuvastatin

NCT02106767
View directory record Official record
Conditions
Healthy
Interventions
Rosuvastatin, Rosuvastatin plus rifampin
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 22, 2020 · Synced Sep 14, 2026, 10:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

GSK1349572 Drug Interaction With Etravirine and Either Darunavir/Ritonavir or Lopinavir/Ritonavir

NCT00867152
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Darunavir, Etravirine, Ritonavir, Lopinavir/ritonavir, GSK1349572
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 21, 2012 · Synced Sep 14, 2026, 10:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Drug-Drug Interaction Between Danoprevir/Low-Dose Ritonavir and Raltegravir in Healthy Volunteers

NCT01531647
View directory record Official record
Conditions
Healthy Volunteer
Interventions
danoprevir, raltegravir, ritonavir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Sep 14, 2026, 10:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-Drug Interaction Study of Losartan and PA21

NCT01324752
View directory record Official record
Conditions
Drug Interaction Potentiation
Interventions
PA21 and Losartan with Food, No PA21; Losartan with food, PA21 with food and Losartan 2 hours later
Drug
Lead sponsor
Vifor Pharma
Industry
Eligibility
20 Years to 50 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Dec 20, 2012 · Synced Sep 14, 2026, 10:45 AM EDT